Immunotherapy with anti‐GD2 monoclonal antibody in infants with high‐risk neuroblastoma

Anti‐GD2 monoclonal antibodies (mAb) improve the prognosis of high‐risk neuroblastoma (HR‐NB). Worldwide experience almost exclusively involves toddlers and older patients treated after multimodality or second‐line therapies, that is, many months postdiagnosis. In contrast, at our center, infants re...

Full description

Saved in:
Bibliographic Details
Published in:International journal of cancer 2023-01, Vol.152 (2), p.259-266
Main Authors: Kushner, Brian H., Modak, Shakeel, Kramer, Kim, Basu, Ellen M., Iglesias‐Cardenas, Fiorella, Roberts, Stephen S., Cheung, Nai‐Kong V.
Format: Article
Language:English
Subjects:
3F8
Analgesics
Antihistamines
Asthma
Bradycardia
Chemotherapy
Cough
Diagnosis
Encephalopathy
Hypotension
Immunotherapy
Infants
Intravenous administration
Medical prognosis
Medical research
Monoclonal antibodies
naxitamab
Neuroblastoma
Patients
Radiation therapy
Remission
Targeted cancer therapy
Toxicity
Urticaria
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Anti‐GD2 monoclonal antibodies (mAb) improve the prognosis of high‐risk neuroblastoma (HR‐NB). Worldwide experience almost exclusively involves toddlers and older patients treated after multimodality or second‐line therapies, that is, many months postdiagnosis. In contrast, at our center, infants received anti‐GD2 mAbs because this immunotherapy started during or immediately after induction chemotherapy. We now report on the feasibility, safety, and long‐term survival in this vulnerable age group. Thirty‐three HR‐NB patients were 2.5× higher (~270 mg/m2/cycle) than 3F8, dinutuximab, and dinutuximab beta (70‐100 mg/m2/cycle). HR‐NB in infants proved to be highly curable. What's new? Anti‐GD2 monoclonal antibodies are a critical part of therapy for high‐risk neuroblastoma (HR‐NB). Because immunotherapy often is initiated months postdiagnosis, however, anti‐GD2 antibodies are used almost exclusively in toddlers and older pediatric patients. Our study examined feasibility, safety, and survival associated with the use of anti‐GD2 antibodies in HR‐NB patients age 19 months or younger. In this age group, anti‐GD2 antibody therapy administered during or immediately following induction chemotherapy was well tolerated. Manageable toxicities enabled outpatient treatment, and overall survival was excellent, including without myeloablative therapy. The findings identif
ISSN:0020-7136
1097-0215
DOI:10.1002/ijc.34233